Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax presented oral data at ASCO 2026 showing a 90% two-year overall survival rate for patients with acute leukemia who resumed Revuforj after stem cell transplant. This compares favorably to a 51% historical benchmark for similar patients treated prior to the availability of menin inhibitors.
Key figures
- Drug Name
- Revuforj (revumenib)
- Cohort size
- 24
- Historical os 2yr
- 51%
- Relapse rate cr1 1yr
- 0%
- Relapse rate cr2 1yr
- 17%
- Post transplant os 2yr
- 90%
- Median follow up months
- 21
- Historical relapse cr1 1yr
- 12%
- Historical relapse cr2 1yr
- 40%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.